The Teófilo Hernando Foundation and the Spanish National Research Council join forces with a collaboration agreement to promote the research and development of new drugs
With this agreement, the FTH takes a fine step forward in its commitment to improve people's health and quality of life.
On May 21, 2024, FTH y el CSIC signed a bilateral collaboration agreement that ranges from basic to clinical research. The collaboration, to be developed through the CSIC's Institute of Medical Chemistry (IQM), will focus on the following areas:
- Preclinical research on new drugs: from the identification of therapeutic targets to the evaluation of the efficacy and safety of new compounds, especially in the field of neurodegenerative diseases.
- Development of new drug delivery technologies: to improve the efficacy of treatments.
- Clinical trials of new drugs: to evaluate their efficacy and safety in patients.
With this agreement, the FTH takes a fine step forward in its commitment to improve people's health and quality of life, putting its efforts into accelerating the research and development of new drugs and treatments thanks to the collaboration and exchange of knowledge with the IQM-CSIC.
The FTH is a non-profit institution dedicated to drug research and development (own research and contract research services) and to the training of researchers and pharmaceutical industry professionals for almost thirty years